NO321455B1 - Anvendelse av en forbindelse som inhiberer bindingen av faktor AP1 til sekvens SEQ ID Nr. 1 til fremstilling av et medikament til behandling av og/eller forebygging av neurodegenerative lidelser. - Google Patents

Anvendelse av en forbindelse som inhiberer bindingen av faktor AP1 til sekvens SEQ ID Nr. 1 til fremstilling av et medikament til behandling av og/eller forebygging av neurodegenerative lidelser. Download PDF

Info

Publication number: NO321455B1
Authority: NO; Norway
Prior art keywords: sequence seq; binding; nucleic acid; factor; vims
Prior art date: 1993-06-30

Application number

NO19954888A

Other languages

English (en)

Norwegian (no)

Other versions

NO954888D0 (no

NO954888L (no

Inventor

Jacques Mallet

Jean-Jacques Robert

Frederic Revah

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-06-30

Filing date

1995-12-01

Publication date

2006-05-15

1995-12-01 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

1995-12-01 Publication of NO954888D0 publication Critical patent/NO954888D0/no

1995-12-01 Publication of NO954888L publication Critical patent/NO954888L/no

2006-05-15 Publication of NO321455B1 publication Critical patent/NO321455B1/no

Links

208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 8
230000027455 binding Effects 0.000 title claims description 28
150000001875 compounds Chemical class 0.000 title claims description 20
230000002265 prevention Effects 0.000 title claims description 7
239000003814 drug Substances 0.000 title claims description 4
238000004519 manufacturing process Methods 0.000 title description 5
150000007523 nucleic acids Chemical class 0.000 claims abstract description 38
102000039446 nucleic acids Human genes 0.000 claims abstract description 34
108020004707 nucleic acids Proteins 0.000 claims abstract description 34
108091023040 Transcription factor Proteins 0.000 claims abstract description 25
102000040945 Transcription factor Human genes 0.000 claims abstract description 25
108020004414 DNA Proteins 0.000 claims abstract description 20
230000003993 interaction Effects 0.000 claims abstract description 14
239000013598 vector Substances 0.000 claims description 12
230000002950 deficient Effects 0.000 claims description 11
241000701161 unidentified adenovirus Species 0.000 claims description 10
241001430294 unidentified retrovirus Species 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 3
241000702421 Dependoparvovirus Species 0.000 claims description 2
241001529453 unidentified herpesvirus Species 0.000 claims description 2
239000013603 viral vector Substances 0.000 claims description 2
239000008186 active pharmaceutical agent Substances 0.000 claims 2
241000700605 Viruses Species 0.000 abstract description 12
230000004770 neurodegeneration Effects 0.000 abstract description 12
229920002307 Dextran Polymers 0.000 abstract description 2
102000007999 Nuclear Proteins Human genes 0.000 abstract description 2
108010089610 Nuclear Proteins Proteins 0.000 abstract description 2
150000002632 lipids Chemical class 0.000 abstract description 2
239000002502 liposome Substances 0.000 abstract description 2
210000004027 cell Anatomy 0.000 description 38
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 24
229930195712 glutamate Natural products 0.000 description 24
108090000623 proteins and genes Proteins 0.000 description 21
238000000034 method Methods 0.000 description 16
230000000694 effects Effects 0.000 description 11
239000002609 medium Substances 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
230000002401 inhibitory effect Effects 0.000 description 7
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
210000002569 neuron Anatomy 0.000 description 6
239000000825 pharmaceutical preparation Substances 0.000 description 6
LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 5
102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 5
108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 5
LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 5
244000166550 Strophanthus gratus Species 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
230000030833 cell death Effects 0.000 description 5
239000000539 dimer Substances 0.000 description 5
239000012634 fragment Substances 0.000 description 5
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 5
229960003343 ouabain Drugs 0.000 description 5
239000013612 plasmid Substances 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
230000001054 cortical effect Effects 0.000 description 4
238000001514 detection method Methods 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
238000005259 measurement Methods 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
102000039537 Jun family Human genes 0.000 description 3
108091067369 Jun family Proteins 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000034994 death Effects 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
239000000284 extract Substances 0.000 description 3
238000000605 extraction Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
108010075796 liver regeneration factor 1 Proteins 0.000 description 3
230000009456 molecular mechanism Effects 0.000 description 3
229960003387 progesterone Drugs 0.000 description 3
239000000186 progesterone Substances 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000010186 staining Methods 0.000 description 3
150000003431 steroids Chemical class 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
229920000936 Agarose Polymers 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
241000701533 Escherichia virus T4 Species 0.000 description 2
102000039539 Fos family Human genes 0.000 description 2
108091067362 Fos family Proteins 0.000 description 2
208000023105 Huntington disease Diseases 0.000 description 2
208000013016 Hypoglycemia Diseases 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000006209 dephosphorylation reaction Methods 0.000 description 2
BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000001037 epileptic effect Effects 0.000 description 2
230000003492 excitotoxic effect Effects 0.000 description 2
231100000063 excitotoxicity Toxicity 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
208000014674 injury Diseases 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000016273 neuron death Effects 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
230000007170 pathology Effects 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
239000011781 sodium selenite Substances 0.000 description 2
229960001471 sodium selenite Drugs 0.000 description 2
235000015921 sodium selenite Nutrition 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
230000008733 trauma Effects 0.000 description 2
229940035722 triiodothyronine Drugs 0.000 description 2
238000012795 verification Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 1
108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
101150096607 Fosl2 gene Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
101150026829 JUNB gene Proteins 0.000 description 1
101150021395 JUND gene Proteins 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
101150064037 NGF gene Proteins 0.000 description 1
102000007399 Nuclear hormone receptor Human genes 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
108700020978 Proto-Oncogene Proteins 0.000 description 1
102000052575 Proto-Oncogene Human genes 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
102100023132 Transcription factor Jun Human genes 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
150000003943 catecholamines Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
238000012411 cloning technique Methods 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
210000003618 cortical neuron Anatomy 0.000 description 1
229940109262 curcumin Drugs 0.000 description 1
235000012754 curcumin Nutrition 0.000 description 1
239000004148 curcumin Substances 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000004060 excitotoxin Substances 0.000 description 1
230000029142 excretion Effects 0.000 description 1
101150064107 fosB gene Proteins 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000028161 membrane depolarization Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
239000002395 mineralocorticoid Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229940097886 phosphorus 32 Drugs 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
239000002243 precursor Substances 0.000 description 1
108010005709 protein kinase C kinase Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Oncology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

NO19954888A 1993-06-30 1995-12-01 Anvendelse av en forbindelse som inhiberer bindingen av faktor AP1 til sekvens SEQ ID Nr. 1 til fremstilling av et medikament til behandling av og/eller forebygging av neurodegenerative lidelser. NO321455B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9307962A FR2707880B1 (fr)	1993-06-30	1993-06-30	Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives.
PCT/FR1994/000771 WO1995001429A1 (fr)	1993-06-30	1994-06-27	Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodegeneratives

Publications (3)

Publication Number	Publication Date
NO954888D0 NO954888D0 (no)	1995-12-01
NO954888L NO954888L (no)	1995-12-01
NO321455B1 true NO321455B1 (no)	2006-05-15

Family

ID=9448720

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19954888A NO321455B1 (no)	1993-06-30	1995-12-01	Anvendelse av en forbindelse som inhiberer bindingen av faktor AP1 til sekvens SEQ ID Nr. 1 til fremstilling av et medikament til behandling av og/eller forebygging av neurodegenerative lidelser.

Country Status (15)

Country	Link
US (1)	US6140112A (sv)
EP (2)	EP0707644B1 (sv)
JP (1)	JP3755825B2 (sv)
KR (1)	KR100517879B1 (sv)
AT (1)	ATE276360T1 (sv)
AU (1)	AU696644B2 (sv)
CA (1)	CA2166318C (sv)
DE (1)	DE69433996T2 (sv)
DK (1)	DK0707644T3 (sv)
ES (1)	ES2227528T3 (sv)
FI (1)	FI120942B (sv)
FR (1)	FR2707880B1 (sv)
NO (1)	NO321455B1 (sv)
PT (1)	PT707644E (sv)
WO (1)	WO1995001429A1 (sv)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6017903A (en)	1996-09-27	2000-01-25	Guilford Pharmaceuticals Inc.	Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en)	1996-09-27	1998-10-20	Guilford Pharmaceuticals Inc.	Treatment of global and focal ischemia using naaladase inhibitors
NZ334780A (en)	1996-09-27	2000-12-22	Guilford Pharm Inc	Use of a NAALADase inhibitor for treating glutamate abnormality and effecting neuronal activity in animals
US6599741B1 (en)	1999-09-14	2003-07-29	Avontec Gmbh	Modulating transcription of genes in vascular cells
DE29916160U1 (de)	1999-09-14	2000-03-09	Cardiogene Gentherapeutische Systeme AG, 40699 Erkrath	Modulation der Transkription von Genen in vaskulären Zellen
CN1315402A (zh) *	2000-03-28	2001-10-03	上海博德基因开发有限公司	一种新的多肽——人淀粉类前体蛋白结合蛋白14和编码这种多肽的多核苷酸
CN1315439A (zh) *	2000-03-29	2001-10-03	上海博德基因开发有限公司	一种新的多肽——人淀粉类前体蛋白结合蛋白9和编码这种多肽的多核苷酸
DE10308045B3 (de)	2003-02-26	2004-06-17	Lurgi Ag	Verfahren und Vorrichtung zur kontinuierlichen Gewinnung freier Weinsäure aus Kaliumhydrogentartrat enthaltenden Rohstoffen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2573436B1 (fr) *	1984-11-20	1989-02-17	Pasteur Institut	Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
WO1991011535A1 (en) *	1990-01-30	1991-08-08	Childrens Hospital Of Los Angeles	Inhibition of transcription by double-stranded oligonucleotides
WO1991018088A1 (en) *	1990-05-23	1991-11-28	The United States Of America, Represented By The Secretary, United States Department Of Commerce	Adeno-associated virus (aav)-based eucaryotic vectors
FR2675803B1 (fr) *	1991-04-25	1996-09-06	Genset Sa	Oligonucleotides fermes, antisens et sens et leurs applications.
GB9114437D0 (en) *	1991-07-03	1991-08-21	Health Lab Service Board	Recombinant adenoviruses and the use thereof for detecting the presence in eukaryotic cells of the expression products of specific genes
FR2708283B1 (fr) *	1994-01-14	1995-10-20	Rhone Poulenc Rorer Sa	Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives.

1993
- 1993-06-30 FR FR9307962A patent/FR2707880B1/fr not_active Expired - Lifetime
1994
- 1994-06-27 EP EP94920987A patent/EP0707644B1/fr not_active Expired - Lifetime
- 1994-06-27 AT AT94920987T patent/ATE276360T1/de active
- 1994-06-27 DE DE69433996T patent/DE69433996T2/de not_active Expired - Lifetime
- 1994-06-27 KR KR1019950706050A patent/KR100517879B1/ko not_active Expired - Lifetime
- 1994-06-27 ES ES94920987T patent/ES2227528T3/es not_active Expired - Lifetime
- 1994-06-27 PT PT94920987T patent/PT707644E/pt unknown
- 1994-06-27 WO PCT/FR1994/000771 patent/WO1995001429A1/fr active IP Right Grant
- 1994-06-27 CA CA002166318A patent/CA2166318C/fr not_active Expired - Lifetime
- 1994-06-27 JP JP50330895A patent/JP3755825B2/ja not_active Expired - Lifetime
- 1994-06-27 AU AU71882/94A patent/AU696644B2/en not_active Expired
- 1994-06-27 EP EP04006618A patent/EP1454984A1/fr not_active Withdrawn
- 1994-06-27 US US08/569,149 patent/US6140112A/en not_active Expired - Lifetime
- 1994-06-27 DK DK94920987T patent/DK0707644T3/da active
1995
- 1995-12-01 NO NO19954888A patent/NO321455B1/no not_active IP Right Cessation
- 1995-12-29 FI FI956353A patent/FI120942B/sv not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69433996D1 (de)	2004-10-21
FR2707880A1 (fr)	1995-01-27
NO954888D0 (no)	1995-12-01
EP0707644A1 (fr)	1996-04-24
ATE276360T1 (de)	2004-10-15
AU7188294A (en)	1995-01-24
JPH08512043A (ja)	1996-12-17
DK0707644T3 (da)	2005-01-17
NO954888L (no)	1995-12-01
FR2707880B1 (fr)	1995-10-06
EP0707644B1 (fr)	2004-09-15
ES2227528T3 (es)	2005-04-01
JP3755825B2 (ja)	2006-03-15
KR960703432A (ko)	1996-08-17
FI956353L (sv)	1995-12-29
WO1995001429A1 (fr)	1995-01-12
FI956353A0 (sv)	1995-12-29
AU696644B2 (en)	1998-09-17
FI120942B (sv)	2010-05-14
CA2166318C (fr)	2009-02-10
EP1454984A1 (fr)	2004-09-08
KR100517879B1 (ko)	2005-12-16
PT707644E (pt)	2005-01-31
CA2166318A1 (fr)	1995-01-12
US6140112A (en)	2000-10-31
DE69433996T2 (de)	2005-09-22

Publication	Publication Date	Title
DK3058071T3 (en)	2018-10-22	: DYNAMIN-2 INHIBITOR FOR THE TREATMENT OF CENTRONUCLEAR MYOPATIA
EP3432905B1 (en)	2022-06-01	Hsv vectors for delivery of nt3 and treatment of cipn
EA020335B1 (ru)	2014-10-30	МИКРО-РНК (mi-РНК) И МИШЕНИ СИГНАЛЬНОГО ПУТИ ДЛЯ ДИАГНОСТИЧЕСКИХ И ТЕРАПЕВТИЧЕСКИХ ЦЕЛЕЙ
US12103952B2 (en)	2024-10-01	Methods for expressing proteins in axons
KR20170098931A (ko)	2017-08-30	뇌 질환을 치료하기 위한 방법 및 조성물
NO321455B1 (no)	2006-05-15	Anvendelse av en forbindelse som inhiberer bindingen av faktor AP1 til sekvens SEQ ID Nr. 1 til fremstilling av et medikament til behandling av og/eller forebygging av neurodegenerative lidelser.
CA2938921A1 (en)	2015-09-11	Codon-optimized nucleotide sequence encoding mg53, its recombinants and use thereof
US20100016221A1 (en)	2010-01-21	Method of degrading protein by chaperone-mediated autophagy
JP2023513188A (ja)	2023-03-30	遺伝子の発現増加のためのｍｉｒｎａ－４８５阻害剤
JP2007190020A (ja)	2007-08-02	特に神経変性疾患の治療のための医薬組成物およびその使用
US12064407B2 (en)	2024-08-20	Endogenous retrovirus-k (ERVK) encodes an alternate envelope protein
US8431119B2 (en)	2013-04-30	Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
JP2024517377A (ja)	2024-04-22	神経変性疾患に用いるための単離または人工ヌクレオチド
Afonso-Reis et al.	2022	The stress granule protein G3BP1 alleviates spinocerebellar ataxia-associated deficits
US20100203111A1 (en)	2010-08-12	G-substrate for the treatment and prevention of parkinson's disease
US8110185B2 (en)	2012-02-07	Method for preventing and treating cardiovascular diseases with BRCA1
FR2708283A1 (fr)	1995-02-03	Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives.
Banner	2007	The thesis of Dina Marie Antonacci is approved

Legal Events

Date	Code	Title	Description
2014-07-07	MK1K	Patent expired